Biosyngen’s liver cancer therapy receives fast track designation
02 Feb 2024
Clinical StudyINDCell TherapyGene TherapyFast Track
Preview
Source: Pharmaceutical Technology
BST02 is being developed to treat liver cancer, including hepatocellular carcinoma and cholangiocarcinoma. Credit: Peakstock / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has granted fast track designation (FTD) to Biosyngen’s T cell therapy BST02 for treating liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
The designation will accelerate the clinical trial process and marketing registration for BST02.
BST02 utilises adoptive immune cell therapy technology, expanding the patient’s own tumour-infiltrating lymphocytes. This approach offers potential benefits over standard tumour-infiltrating lymphocyte (TIL) therapies, including the ability to be cryopreserved and transported and a reduced requirement for high doses of interleukin-2.
In October 2023, the company received FDA approval to commence the Phase I/II clinical trials of the cell therapy.
The China National Drug Administration’s Center for Drug Evaluation granted approval for the trial in December.
See Also:Vivet wins $5.3m grant to develop gene therapy for rare metabolic disorder
Preview
Source: Pharmaceutical Technology
CMS sets up negotiating framework for expensive sickle cell disease gene therapies
Preview
Source: Pharmaceutical Technology
This marks a significant milestone as BST02 becomes the first TIL cell therapy drug for liver cancer to enter clinical stages globally.
Biosyngen aims to continue its research efforts to improve patient outcomes worldwide.
Biosyngen co-founder and CEO Michelle Chen expressed her gratitude to the FDA for recognising the company’s fourth product.
She highlighted the company’s commitment to advancing cancer cell therapy across the globe and offering new treatments for a diverse patient population.
Chen reaffirmed the company’s dedication to using its advanced technology platforms to deliver accessible therapies for patients around the world.
In September 2023, the company received FDA IND clearance for a Phase I/II trial of its therapy, BRL03, to treat lung cancer, gastric cancer and other advanced solid tumours.
BRL03 is the first T cell receptor product developed by the company to enter the clinics.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.